⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

モデル
薬剤
インサイト

Company

CROパートナー
Contact Us
Privacy Policy

© 2025 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Survodutide (Survodutide) | 加速させる、線維化研究を

Home/Drugs/Survodutide

Survodutide

Survodutide

Phase 3

Sponsor: Boehringer Ingelheim

Indication: MASH

Mechanism of Action

GLP-1/Glucagon Dual Agonist

Target: GLP-1Target: Glucagon

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT05896384

A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood

Phase:PHASE1Org:Boehringer Ingelheim

COMPLETED

Relevant Publications (PubMed)

Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR/GLP-1R agonist survodutide in mice.

Long F, Challa TD, Efthymiou V et al.

Diabetes Obes Metab2025 Dec 12

Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed.

Martínez-Castelao A, Górriz JL, Fernández-Fernández B et al.

J Clin Med2025 Nov 23

Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon.

Abdelrahman RM, Musa TH, Arbab IA et al.

J Obes2025

Survodutide for the Treatment of Obesity: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial.

Validated Models

This drug has been validated in the following preclinical models:

NCT06492135

A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body

Phase:PHASE1Org:Boehringer Ingelheim

COMPLETEDNCT06309992

A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight

Phase:PHASE3Org:Boehringer Ingelheim

COMPLETEDNCT05296733

A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906

Phase:PHASE1Org:Boehringer Ingelheim

RECRUITINGNCT06745284

A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity

Phase:PHASE1Org:Boehringer Ingelheim

View all trials on ClinicalTrials.gov

Platz E, Kaplan LM, le Roux CW et al.

JACC Heart Fail2025 Nov 3

Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.

Wharton S, le Roux CW, Bozkurt B et al.

Diabetes Obes Metab2025 Nov 11

View more on PubMed